Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 2

Interventions

Docetaxel 390pembrolizumab 325Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Chemoprevention × Genitourinary × Clear all
NCT00553124 2014-01-10

Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
3,400 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00553345 2014-01-10

Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
515 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡